Phospholipid oxidation and carotenoid supplementation in Alzheimer's disease patients

Free Radical Biology and Medicine

Volumn 108, Issue , 2017, Pages 77-85

  Ademowo, O S ^a   Dias, H K I ^a   Milic, I ^a   Devitt, A ^a   Moran, R ^b   Mulcahy, R ^c   Howard, A N ^d,e   Nolan, J M ^b   Griffiths, H R ^a,f  

^a ASTON UNIVERSITY   (United Kingdom)

^b Ireland   (Ireland)

^c WATERFORD REGIONAL HOSPITAL   (Ireland)

^d Howard Foundation   (United Kingdom)

^e DOWNING COLLEGE   (United Kingdom)

^f UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

Cognitive function; Lipid peroxidation; Lutein; Mass spectrometry; Meso zeaxanthin; Oxidative stress; POVPC; Supplementation; Zeaxanthin

Indexed keywords

1 PALMITOYL 2 (5' OXOVALEROYL) SN GLYCERO 3 PHOSPHOCHOLINE; 8 ISOPROSTANE; CAROTENOID; CHOLINESTERASE INHIBITOR; MESO ZEAXANTHIN; PHOSPHOLIPID; PLACEBO; SUNFLOWER OIL; UNCLASSIFIED DRUG; XANTHOPHYLL; ZEAXANTHIN; 1-PALMITOYL-2-(5-OXOVALEROYL)-SN-GLYCERO-3-PHOSPHORYLCHOLINE; ANTIOXIDANT; BIOLOGICAL MARKER; ETHER PHOSPHOLIPID; MESO-ZEAXANTHIN; REACTIVE OXYGEN METABOLITE;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CLINICAL OUTCOME; COGNITION; COLORIMETRY; CONTROLLED STUDY; CORRELATION ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FERRIC REDUCING ANTIOXIDANT POWER ASSAY; HUMAN; LIPID PEROXIDATION; MALE; MEASUREMENT ACCURACY; MULTIPLE REACTION MONITORING; PHOSPHOLIPID BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; SUPPLEMENTATION; TANDEM MASS SPECTROMETRY; BLOOD; CHEMISTRY; COGNITIVE DEFECT; DIETARY SUPPLEMENT; METABOLISM; MULTIMODALITY CANCER THERAPY; OXIDATION REDUCTION REACTION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIOXIDANTS; BIOMARKERS; CAROTENOIDS; COGNITION DISORDERS; COMBINED MODALITY THERAPY; DIETARY SUPPLEMENTS; FEMALE; HUMANS; LIPID PEROXIDATION; LUTEIN; MALE; OXIDATION-REDUCTION; PHOSPHOLIPID ETHERS; PHOSPHOLIPIDS; REACTIVE OXYGEN SPECIES; ZEAXANTHINS;

EID: 85015761126     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2017.03.008     Document Type: Article

References (44)

1. [1] Simoncini, C., Orsucci, D., Caldarazzo Ienco, E., Siciliano, G., Bonuccelli, U., Mancuso, M., Alzheimer's pathogenesis and its link to the mitochondrion. Oxid. Med. Cell. Longev., 2015, 2015, 803942.
2. [2] Swerdlow, R.H., Brain aging, Alzheimer's disease, and mitochondria. Biochim. Biophys. Acta 1812:12 (2011), 1630–1639.
3. [3] Fevziye, S., Duygu, K.D., Huseyin, V., Ibrahim, E., Ikbal, I., Recep, S., Namik, D., Plasma 8-isoPGF2α and serum melatonin levels in patients with minimal cognitive impairment and Alzheimer disease. Turk. J. Med. Sci. 45 (2015), 1073–1077.
4. [4] Mariani, E., Polidori, M.C., Cherubini, A., Mecocci, P., Oxidative stress in brain aging, neurodegenerative and vascular diseases: an overview. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 827:1 (2005), 65–75.
5. [5] Samhan-Arias, A.K., Ji, J., Demidova, O.M., Sparvero, L.J., Feng, W., Tyurin, V., Amoscato, A.A., Oxidized phospholipids as biomarkers of tissue and cell damage with a focus on cardiolipin. Biochim. Biophys. Acta 1818:10 (2012), 2413–2423.
6. [6] O'Donnell, V.B., Mass spectrometry analysis of oxidized phosphatidylcholine and phosphatidylethanolamine. Biochim. Biophys. Acta 1811:11 (2011), 818–826.
7. [7] Bochkov, V.N., Oskolkova, O.V., Birukov, K.G., Levonen, A.-L., Binder, C.J., Stöckl, J., Generation and biological activities of oxidized phospholipids. Antioxid. Redox Signal. 12:8 (2010), 1009–1059.
8. [8] Philippova, M., Resink, T., Erne, P., Bochkov, V., Oxidised phospholipids as biomarkers in human disease. Swiss Med. Wkly., 144, 2014, w14037.
9. [9] Reis, A., Spickett, C.M., Chemistry of phospholipid oxidation. Biochim. Biophys. Acta 1818:10 (2012), 2374–2387.
10. [10] Castro-Perez, J.M., Kamphorst, J., DeGroot, J., Lafeber, F., Goshawk, J., Yu, K., Hankemeier, T., Comprehensive LC-MS E lipidomic analysis using a shotgun approach and its application to biomarker detection and identification in osteoarthritis patients. J. Proteome Res. 9:5 (2010), 2377–2389.
11. [11] Xiang, Y., Lam, S.M., Shui, G., What can lipidomics tell us about the pathogenesis of Alzheimer disease*. Biol. Chem. 396:12 (2015), 1281–1291.
12. [12] Pratico, D., Lawson, J.A., FitzGerald, G.A., Cyclooxygenase-dependent formation of the isoprostane, 8-epi prostaglandin F2 alpha. J. Biol. Chem. 270:17 (1995), 9800–9808.
13. [13] Haller, E., Stübiger, G., Lafitte, D., Lindner, W., Lämmerhofer, M., Chemical recognition of oxidation-specific epitopes in low-density lipoproteins by a nanoparticle based concept for trapping, enrichment, and liquid chromatography–tandem mass spectrometry analysis of oxidative stress biomarkers. Anal. Chem. 86:19 (2014), 9954–9961.
14. [14] Qin, J., Goswami, R., Balabanov, R., Dawson, G., Oxidized phosphatidylcholine is a marker for neuroinflammation in multiple sclerosis brain. J. Neurosci. Res. 85:5 (2007), 977–984.
15. [15] Hartman, T.J., Baer, D.J., Graham, L.B., Stone, W.L., Gunter, E.W., Parker, C.E., Taylor, P.R., Moderate alcohol consumption and levels of antioxidant vitamins and isoprostanes in postmenopausal women. Eur. J. Clin. Nutr. 59:2 (2005), 161–168.
16. [16] Benzie, I.F., Strain, J.J., The ferric reducing ability of plasma (FRAP) as a measure of ‘antioxidant power’: the FRAP assay. Anal. Biochem. 239:1 (1996), 70–76.
17. [17] Moslemnezhad, A., Mahjoub, S., Moghadasi, M., Altered plasma marker of oxidative DNA damage and total antioxidant capacity in patients with Alzheimer's disease. Casp. J. Intern. Med. 7:2 (2016), 88–92.
18. [18] Dineley, K.T., Jahrling, J.B., Denner, L., Insulin resistance in Alzheimer's disease. Neurobiol. Dis. 72 (2014), 92–103.
19. [19] Du, F., Wang, L., Zhang, Y., Jiang, W., Sheng, H., Cao, Q., Zhang, J.Z., Role of GADD45 in the regulation of synovial fluid T cell apoptosis in rheumatoid arthritis. Clin. Immunol. 128:2 (2008), 238–247.
20. [20] Block, G., Patterson, B., Subar, A., Fruit, vegetables, and cancer prevention: a review of the epidemiological evidence. Nutr. Cancer 18:1 (1992), 1–29.
21. [21] Kelly, D., Coen, R.F., Akuffo, K.O., Beatty, S., Dennison, J., Moran, R., Nolan, J.M., Cognitive function and its relationship with macular pigment optical density and serum concentrations of its constituent carotenoids. J. Alzheimers Dis. 48:1 (2015), 261–277.
22. [22] Polidori, M.C., Mattioli, P., Aldred, S., Cecchetti, R., Stahl, W., Griffiths, H., Mecocci, P., Plasma antioxidant status, immunoglobulin g oxidation and lipid peroxidation in demented patients: relevance to Alzheimer disease and vascular dementia. Dement. Geriatr. Cogn. Disord. 18:3–4 (2004), 265–270.
23. [23] Dias, I.H.K., Polidori, M.C., Li, L., Weber, D., Stahl, W., Nelles, G., Griffiths, H.R., Plasma levels of HDL and carotenoids are lower in dementia patients with vascular comorbidities. J. Alzheimers Dis. 40:2 (2014), 399–408.
24. [24] Anlasik, T., Sies, H., Griffiths, H.R., Mecocci, P., Stahl, W., Polidori, M.C., Dietary habits are major determinants of the plasma antioxidant status in healthy elderly subjects. Br. J. Nutr. 94:5 (2005), 639–642.
25. [25] Nolan, J.M., Loskutova, E., Howard, A., Mulcahy, R., Moran, R., Stack, J., Beatty, S., The impact of supplemental macular carotenoids in Alzheimer's disease: a randomized clinical trial. J. Alzheimers Dis. 44:4 (2015), 1157–1169.
26. [26] Nolan, J.M., Loskutova, E., Howard, A.N., Moran, R., Mulcahy, R., Stack, J., Beatty, S., Macular pigment, visual function, and macular disease among subjects with Alzheimer's disease: an exploratory study. J. Alzheimers Dis. 42:4 (2014), 1191–1202.
27. [27] Matyash, V., Liebisch, G., Kurzchalia, T.V., Shevchenko, A., Schwudke, D., Lipid extraction by methyl-tert-butyl ether for high-throughput lipidomics. J. Lipid Res. 49:5 (2008), 1137–1146.
28. [28] Stewart, J.C.M., Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal. Biochem. 104:1 (1980), 10–14.
29. [29] Shrivastava, A., Gupta, V., Methods for the determination of limit of detection and limit of quantitation of the analytical methods. Chron. Young-. Sci., 2(1), 2011, 21.
30. [30] Partani, P., Verma, S.M., Monif, T., Development and validation of an LC-MS-MS method for determination of simvastatin and simvastatin acid in human plasma: application to a pharmacokinetic study. J. Chromatogr. Sci. 54:8 (2016), 1385–1396.
31. [31] Mapstone, M., Cheema, A.K., Fiandaca, M.S., Zhong, X., Mhyre, T.R., MacArthur, L.H., Federoff, H.J., Plasma phospholipids identify antecedent memory impairment in older adults. Nat. Med. 20:4 (2014), 415–418.
32. [32] Li, L., Willets, R.S., Polidori, M.C., Stahl, W., Nelles, G., Sies, H., Griffiths, H.R., Oxidative LDL modification is increased in vascular dementia and is inversely associated with cognitive performance. Free Radic. Res. 44:3 (2010), 241–248.
33. [33] Watson, A.D., Leitinger, N., Navab, M., Faull, K.F., Hörkkö, S., Witztum, J.L., Berliner, J.A., Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo. J. Biol. Chem. 272:21 (1997), 13597–13607.
34. [34] Gandhi, S., Abramov, A.Y., Mechanism of oxidative stress in neurodegeneration. Oxid. Med. Cell. Longev., 2012, 2012 11 pages.
35. [35] McNulty, H.P., Byun, J., Lockwood, S.F., Jacob, R.F., Mason, R.P., Differential effects of carotenoids on lipid peroxidation due to membrane interactions: x-ray diffraction analysis. Biochim. Biophys. Acta 1768:1 (2007), 167–174.
36. [36] Donaldson, M., Development of a rapid, simple assay of plasma total carotenoids. BMC Res. Notes, 5(1), 2012, 521.
37. [37] Carughi, A., Hooper, F.G., Plasma carotenoid concentrations before and after supplementation with a carotenoid mixture. Am. J. Clin. Nutr. 59:4 (1994), 896–899.
38. [38] Praticò, D., Lee, M.Y., Trojanowski, V., Q, J., Rokach, J., Fitzgerald, G.A., Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo. FASEB J. 12:15 (1998), 1777–1783.
39. [39] Klein, T., Reutter, F., Schweer, H., Seyberth, H.W., Nüsing, R.M., Generation of the isoprostane 8-epi-prostaglandin F2alpha in vitro and in vivo via the cyclooxygenases. J. Pharmacol. Exp. Ther. 282:3 (1997), 1658–1665.
40. [40] Faul, F., Erdfelder, E., Lang, A.-G., Buchner, A., G*Power 3: a flexible statistical Power analysis program for the social, behavioral, and biomedical sciences. Behav. Res. Methods 39:2 (2007), 175–191.
41. [41] Grasset, E.K., Duhlin, A., Agardh, H.E., Ovchinnikova, O., Hägglöf, T., Forsell, M.N., Karlsson, M.C.I., Sterile inflammation in the spleen during atherosclerosis provides oxidation-specific epitopes that induce a protective B-cell response. Proc. Natl. Acad. Sci. USA 112:16 (2015), E2030–E2038.
42. [42] Duewell, P., Kono, H., Rayner, K.J., Sirois, C.M., Vladimer, G., Bauernfeind, F.G., Latz, E., NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464:7293 (2010), 1357–1361.
43. [43] Birukova, A.A., Starosta, V., Tian, X., Higginbotham, K., Koroniak, L., Berliner, J.A., Birukov, K.G., Fragmented oxidation products define barrier disruptive endothelial cell response to OxPAPC. Transl. Res. 161:6 (2013), 495–504.
44. [44] Dias, I.H., Brown, C.L.R., Polidori-Nelles, M.C., Lip, G.Y., Griffiths, H.R., LDL-lipids from patients with hypercholesterolaemia and Alzheimer's disease are inflammatory to microvascular endothelial cells: mitigation by statin intervention. Clin. Sci. 129:12 (2015), 1195–1206.